Skip to content

Novel 4-Anilinopyrimidine-N-Acylhydrazone derivatives as dual EGFRWT/VEGFR-2 tyrosine kinase inhibitors against non-small cell lung Cancer: Design, synthesis, biological evaluation, and computational studies.

Nov 2026 · Bioorganic chemistry (Print) · Vol 185, pp. 110719 · 0 citations · 85 references
Medicine

TL;DR

Two new series of 4-Anilinopyrimidine-N-acylhydrazone derivatives (7a-k and 9a-e) were designed and synthesized as potent dual EGFRWT/VEGFR-2 tyrosine kinase inhibitors, showing potent cytotoxicity against A549 NSCLC cells and stable complex formation of 9e with both targets.

Abstract

Two new series of 4-Anilinopyrimidine-N-acylhydrazone derivatives (7a-k and 9a-e) were designed and synthesized as potent dual EGFRWT/VEGFR-2 tyrosine kinase inhibitors. The in vitro antiproliferative activity of the compounds against MDA-MB-231, HepG2 and A549 cancer cell lines revealed derivatives 7e, 7i, 7k, 9a, and 9e were the most active, showing potent cytotoxicity against A549 NSCLC cells with IC50 values in the range of 1.25 to 7.20 μM compared to erlotinib (IC50 = 4.07 μM) and sorafenib (IC50 = 9.51 μM). Compound 9e was identified as the lead derivative with the most potent cytotoxicity against A549 cells (IC50 = 1.25 ± 0.11 μM), displaying 3.3- and 7.6-fold higher potency than erlotinib and sorafenib, respectively, with an excellent tumor selectivity over normal WI-38 fibroblasts (SI = 187.5). Enzyme inhibition assays confirmed potent dual kinase activity of 9e against EGFRWT (IC50 = 0.074 μM) and VEGFR-2 (IC50 = 0.055 μM) compared to erlotinib (EGFRWT IC50 = 0.043 μM) and sorafenib (VEGFR-2 IC50 = 0.098 μM). Annexin V-FITC/PI flow cytometry revealed apoptosis as the primary form of cell death in A549 cells induced by 9e. Molecular docking into EGFRWT and VEGFR-2 revealed that 9e reproduces the critical binding contacts of both reference inhibitors and forms additional unique interactions, rationalizing its superior potency. The molecular dynamics simulations demonstrated stable complex formation of 9e with both targets, with favorable MM-GBSA binding free energies of -26.23 and - 38.97 kcal/mol for EGFRWT and VEGFR-2, respectively.

View source

Similar papers

Open access Sep 2026

Design, synthesis, and molecular modeling of quinoline-linked diphenylpyrazoles as multitarget EGFR, VEGFR-2, and COX-2 inhibitors with anticancer, anti-inflammatory and apoptosis-inducing properties.

A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.

Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al. · 0 citations
Open access Nov 2026

Discovery of novel 1,3,4-thiadiazole derivatives as potential dual EGFR/VEGFR inhibitors with activity against breast, colon, and liver cancer cells: biological evaluation and molecular docking investigation

New derivatives of the 1,3,4-thiadiazole scaffold were synthesized and evaluated for their cytotoxic effects on breast (MCF-7), hepatic (HepG-2), and colorectal (HCT-116) carcinomas. The most active compounds (7, 8, 15, and 16) exhibited substantial, broad-spectrum anticancer efficacy, with IC50 values ranging from 1.5...

Amany Belal, M. A. Abourehab, Reem I. Alsantali et al. · 0 citations
Open access Sep 2026

Synthesis and Evaluation of New 1, 4-Dihydropyridine Derivatives as Potential Breast Cancer Therapeutics: HER2 Inhibition Efficacy Study Using MCF-7 and SK-BR-3 Cells and Molecular Docking

The derivatives of 1,4-Dihydropyridine compound have gained significant interest for their potential-anticancer properties particularly in targeting breast-cancer. The study aimed to synthesize and evaluate the anticancer activity of four novel 1,4-dihydropyridine derivatives (5a–d) against breast cancer cell lines MCF...

Abdulrhman Y. Khalifa · 0 citations
Open access Sep 2026

5-Arylidene-3-aryl-imidazol-4-ones as dual VEGFR-2/c-Met inhibitors: design, synthesis, and anticancer evaluation.

Cancer remains a major global health challenge characterized by uncontrolled proliferation, angiogenesis, and metastasis. Dysregulation of receptor tyrosine kinases, particularly VEGFR-2 and c-Met, plays a central role in tumor growth and vascularization, rendering their dual inhibition an attractive therapeutic strate...

Hend E. Elshafey, Mostafa M. Elbadawi, Marwa Balaha et al. · 0 citations
Open access Nov 2026

Quinazoline derivatives with dual EGFR and VEGFR-2 inhibition: insights from docking, molecular dynamics, and in vivo studies

Tumor growth, angiogenesis, and metastasis are influenced by EGFR and VEGFR-2; therefore, dual targeting of EGFR and VEGFR-2 is an attractive approach for cancer management. Here, novel quinazoline analogues 4–23 were designed and synthesized as dual EGFR and VEGFR-2 TK inhibitors. In vitro enzymatic inhibitory activit...

Asmaa S. A. Yassen, Mohamed S. Nafie, Safaa M. Kishk et al. · 0 citations
Oct 2026

Design, synthesis, biological evaluation and computational investigation of Thiadiazole Benzimidazole derivatives bearing a Chlorophyrimidine pharmacophore as potent CLK2 inhibitors and anticancer agents.

Cdc2-like kinase 2 (CLK2) has emerged as an attractive anticancer therapeutic target because of its crucial role in pre-mRNA splicing and tumor growth. Here, we designed and synthesized a novel series of thiadiazole-based benzimidazole derivatives 15a-l incorporating chloropyrimidine pharmacophore and evaluated for CLK...

T. Aziz, Rafaqat Hussain, H. Sarfraz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.